R-Biopharm AG And Merck KGaA, Darmstadt, Germany Enter Into Collaboration On Developing And Launching Companion Diagnostics
Darmstadt, Germany, March 22, 2016 - R-Biopharm AG announced today it has entered into an agreement with Merck KGaA, Darmstadt, Germany to collaborate on developing companion diagnostics.
The agreement constitutes the first collaboration between the two companies, covering research, development and launching of novel companion diagnostics. The project provides framework for further collaborations across a potentially wide range of therapeutic areas and a broad range of technologies.
"We are very pleased to partner with Merck KGaA, Darmstadt, Germany one of the world's leading healthcare companies", said Dr. Frank Apostel, Vice President Companion Diagnostics, R-Biopharm AG. "This partnership is an example to the level of expertise and service R-Biopharm is committed to delivering to our partners in companion diagnostics."
Companion diagnostics play a central role in the field of personalized medicine. They help to find specific therapies matching to individual patients and thereby improve patient care and reduce healthcare costs.
Financial terms of the agreement were not disclosed.
The agreement constitutes the first collaboration between the two companies, covering research, development and launching of novel companion diagnostics. The project provides framework for further collaborations across a potentially wide range of therapeutic areas and a broad range of technologies.
"We are very pleased to partner with Merck KGaA, Darmstadt, Germany one of the world's leading healthcare companies", said Dr. Frank Apostel, Vice President Companion Diagnostics, R-Biopharm AG. "This partnership is an example to the level of expertise and service R-Biopharm is committed to delivering to our partners in companion diagnostics."
Companion diagnostics play a central role in the field of personalized medicine. They help to find specific therapies matching to individual patients and thereby improve patient care and reduce healthcare costs.
Financial terms of the agreement were not disclosed.